Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MILAN--(BUSINESS WIRE)--July 15, 2013 -- Sorin Group (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the signing of a supply agreement for the manufacturing of certain components of the Lotus(TM) Aortic Valve System, Boston Scientific Corporation's second-generation TAVR (Transcatheter Aortic Valve Replacement) technology. Under the terms of this agreement, Sorin Group will perform certain manufacturing steps related to the tissue valve in its facility in Vancouver (Canada).
"This agreement recognizes the strong valve manufacturing experience that Sorin Group has accumulated across its European and North American operations," said Michel Darnaud, President of Sorin Group, Cardiac Surgery Business Unit, "building on more than 40 years of innovation, development, clinical validation and commercialization in the field of mechanical and tissue prosthetic heart valves."
The Lotus(TM) Aortic Valve System is an investigational device worldwide, limited by applicable law to investigational use and not available for sale.
About Sorin Group
Sorin Group (www.sorin.com), is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, the Company focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement products) and Cardiac Rhythm Management (pacemakers, defibrillators, cardiac resynchronization devices). Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.
For more information, please visit: www.sorin.com
CONTACT: Martine Konorski, Tel: +33 (0)1 46 01 33 78
Director, Corporate Communications
Sorin Group
Mobile: +33 (0)6 76 12 67 73
e-mail: martine.konorski@sorin.com
or
Francesca Rambaudi, Tel: +39 02 69969716
Director, Investor Relations
Sorin Group
e-mail: investor.relations@sorin.com
SOURCE: Sorin Group
Visit http://djnweurope.ar.wilink.com/?ticker=IT0003544431 or call +44 (0)208 391 6028
Help employers find you! Check out all the jobs and post your resume.
MILAN--(BUSINESS WIRE)--July 15, 2013 -- Sorin Group (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the signing of a supply agreement for the manufacturing of certain components of the Lotus(TM) Aortic Valve System, Boston Scientific Corporation's second-generation TAVR (Transcatheter Aortic Valve Replacement) technology. Under the terms of this agreement, Sorin Group will perform certain manufacturing steps related to the tissue valve in its facility in Vancouver (Canada).
"This agreement recognizes the strong valve manufacturing experience that Sorin Group has accumulated across its European and North American operations," said Michel Darnaud, President of Sorin Group, Cardiac Surgery Business Unit, "building on more than 40 years of innovation, development, clinical validation and commercialization in the field of mechanical and tissue prosthetic heart valves."
The Lotus(TM) Aortic Valve System is an investigational device worldwide, limited by applicable law to investigational use and not available for sale.
About Sorin Group
Sorin Group (www.sorin.com), is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, the Company focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement products) and Cardiac Rhythm Management (pacemakers, defibrillators, cardiac resynchronization devices). Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.
For more information, please visit: www.sorin.com
CONTACT: Martine Konorski, Tel: +33 (0)1 46 01 33 78
Director, Corporate Communications
Sorin Group
Mobile: +33 (0)6 76 12 67 73
e-mail: martine.konorski@sorin.com
or
Francesca Rambaudi, Tel: +39 02 69969716
Director, Investor Relations
Sorin Group
e-mail: investor.relations@sorin.com
SOURCE: Sorin Group
Visit http://djnweurope.ar.wilink.com/?ticker=IT0003544431 or call +44 (0)208 391 6028
Help employers find you! Check out all the jobs and post your resume.
